A signaling pathway AKTing up in schizophrenia.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 18497888.
- Also identified by DOI 10.1172/JCI35931 and PMC identifier 2391280.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The serine/threonine protein kinase AKT (also known as PKB) signaling pathway has been associated with several human diseases, including schizophrenia. Studies in preclinical models have demonstrated that impaired AKT signaling affects neuronal connectivity and neuromodulation and have identified AKT as a key signaling intermediary downstream of dopamine (DA) receptor 2 (DRD2), the best-established target of antipsychotic drugs. A study by Tan et al. in this issue of the JCI strengthens links among AKT signaling, DA transmission, and cognition in healthy individuals and offers potential avenues to explore in an effort to find more effective pharmacotherapies for schizophrenia and related disorders (see the related article beginning on page 2200).
Medical subject headings
- Gene Expression Regulation
- Proto-Oncogene Proteins c-akt
- Schizophrenia
- Signal Transduction